Historical AI Consensus

This page preserves the research and market snapshot packaged for this batch. It is not updated with later prices or revised advisor outputs.

Symbol: VCEL.NASDAQ
Batch: 7
Published: September 20, 2026
AI Advisors: 14

Historical AI Consensus Investment Thesis

Vericel (VCEL) Stock Forecast and AI Rating

Deep analysis published Sep 21 2026Original pricing snapshot Sep 18 2026

Publisher

Russlan Ramdowar

12 min read

Published 1-Year and 5-Year Forecast Outlook

Forecast targets and rating

Published batch rating

NEUTRAL

Calculated from the frozen synthesized path using the same return, horizon, volatility and dividend rules as individual opinions.

2027

1-Year

NEUTRAL

$44

+10.6%

2031

5-Year

NEUTRAL

$68

+70.2%

Published batch insight

Cellular Therapy Cash Inflection Confronts Restrictive Valuation Compression In Orthopedic Expansion

Reports show high consensus that completed manufacturing expansion and arthroscopic sports medicine adoption accelerate cash flow generation. However, sharp valuation divergence persists regarding whether surging operational earnings can overcome multiple compression driven by elevated interest rates, commercial payer prior authorization friction, and prospective allogeneic technological obsolescence.

Deep Forecast Analysis by iPulse AI Engine

This analysis preserves the original published batch. Audit published forecasts in full transparency

J.P. Morgan (Titan), Superintelligence (Anthropologist), Universal Investor (Polymath), Sherlock Holmes (Whistleblower), Warren Buffett (Value Purist), Machiavelli (Insider), Elon Musk (Visionary), Michael Burry (Vulture), Ray Dalio (Strategist). Some archetypes run in multiple modes, resulting in 14 advisors total.

Computed on these frontier AI models

Gemini

Claude

ChatGPT

Full published thesis

Executive Summary

If you invested $10,000 in Vericel at the forecast anchor (2026-09-18): $17,021 in five years versus $13,892 for S&P 500 benchmark.

Vericel · Synthesized ConsensusS&P 500 benchmark

Figure: Five-year synthesized consensus value path for Vericel compared with S&P 500 benchmark. The path uses the synthesizer’s normalized opinion weights.

20-quarter synthesized forecastPrice targets, quarterly returns and the reasoning behind each stepView table

Frozen forecast from 18 Sept 2026. Prices in USD; returns exclude dividends. Each quarter is compounded from the previous quarter.

Anchor: 40.02 USD1-year price return: +10.65%5-year price return: +70.21%

Swipe the table horizontally to read every column.

Twenty quarterly synthesized price forecasts in USD, with returns and rationale
Quarter	Target (USD)	Quarter return	Total return	Forecast rationale
Q4 2026	41.68	+4.15%	+4.15%	Year-end insurance deductible exhaustion accelerates fourth-quarter surgical implants, while initial share repurchase execution supports prices. However, elevated Treasury yields and macroeconomic discount-rate pressure cap broader multiple expansion, keeping net quarterly appreciation moderate.
Q1 2027	41.63	-0.12%	+4.03%	Annual deductible resets and insurance re-authorizations induce seasonal procedure slowdowns. Headline operating margins contract amid dual-facility depreciation, while persistent central bank rate discipline dampens speculative sentiment, prompting routine first-quarter valuation consolidation across medtech equities.
Q2 2027	42.71	+2.59%	+6.72%	Second-quarter surgical volumes rebound as newly trained sports medicine surgeons increase arthroscopic case frequency. Commercial manufacturing runs at Burlington demonstrate early batch efficiencies, expanding gross margins and generating positive operating cash flow.
Q3 2027	44.28	+3.68%	+10.65%	Summer sports injury volume maintains consistent biopsy velocity, while federal burn procurement shipments under the BARDA contract provide non-cyclical revenue baselines. Moderating capital spending supports trailing cash flow, offsetting broader equity market multiple stagnation.
Q4 2027	46.86	+5.83%	+17.10%	A potent fourth-quarter procedural rush drives record cartilage implant revenue. Operating leverage becomes clearly visible as Burlington fixed overhead absorbs, prompting sell-side earnings revisions and strong year-end institutional accumulation despite prevailing interest-rate headwinds.
Q1 2028	46.44	-0.90%	+16.04%	Routine first-quarter procedural lulls and healthcare deductible resets temporarily soften reported quarterly net income. Active open-market share repurchases provide downside price support, buffering equity valuation as investors evaluate full-year operational guidance.
Q2 2028	48.68	+4.83%	+21.65%	Spring surgical conversions accelerate alongside encouraging clinical enrollment progress in the MASCOT ankle trial. Higher batch throughput at Burlington lowers unit production costs, reinforcing gross margins above 75% and driving positive earnings momentum.
Q3 2028	49.69	+2.07%	+24.17%	Seasonal elective surgery moderation intersects with commercial payer prior-authorization scrutiny, slightly extending biopsy conversion cycles. Steady burn care cash flows and disciplined commercial expenditure preserve operating margins, sustaining orderly trading within the multi-year band.
Q4 2028	51.99	+4.62%	+29.90%	Year-end surgical concentration pushes full-year revenue past guidance milestones as Burlington cleanrooms achieve higher capacity utilization. Sinking capital intensity lifts free cash flow conversion, enabling accretive share retirements that enhance per-share fundamental valuation.
Q1 2029	52.26	+0.53%	+30.59%	Predictable post-holiday procedure deceleration and winter scheduling delays prompt modest seasonal profit taking. Unencumbered balance-sheet liquidity and zero funded debt insulate operations completely from broader macroeconomic credit volatility, maintaining price stability.
Q2 2029	54.66	+4.59%	+36.59%	Pivotal clinical readout announcements for the ankle cartilage indication expand long-term total addressable market expectations. Second-quarter sports medicine case volumes rebound strongly, while automated processing efficiencies lift trailing operating income to fresh highs.
Q3 2029	56.12	+2.67%	+40.23%	Core knee repair growth normalizes toward steady mid-teens compounding, while emerging clinical presentations of alternative allogeneic scaffolds temper long-term terminal valuation multiples. Continued share repurchases and international regulatory progress support steady price consolidation.
Q4 2029	58.89	+4.94%	+47.16%	Another robust fourth-quarter procedural performance generates record annual operating cash flow exceeding eighty million dollars. High-margin autologous cellular demand confirms business model durability, overcoming broader macroeconomic deceleration through biological standard-of-care entrenchment.
Q1 2030	59.11	+0.36%	+47.69%	Annual surgical schedule resets and transitional operating expenses ahead of supplemental regulatory filings induce minor quarterly margin compression. Substantial cash reserves and absence of debt maturities reassure institutional holders, preventing protracted valuation drawdowns.
Q2 2030	61.53	+4.11%	+53.76%	Regulatory progress and commercial preparations for expanded extremity indications re-energize orthopedic surgeon interest. Burlington operates at mature batch economics, generating robust quarterly free cash flow that funds ongoing capital return programs.
Q3 2030	62.34	+1.31%	+55.77%	Procedural demand demonstrates steady high-single-digit expansion across established sports medicine networks. Terminal growth expectations stabilize around mature medtech benchmarks, keeping valuation multiples aligned with expanding GAAP earnings power rather than speculative platform expansion.
Q4 2030	64.98	+4.24%	+62.38%	Record fourth-quarter procedure density across knee and burn franchises delivers strong year-end earnings. Operating margins sustainably approach the high teens as fixed infrastructure costs distribute across mature volume, driving solid annual equity compounding.
Q1 2031	64.68	-0.47%	+61.62%	Familiar first-quarter procedural resets and routine healthcare policy debates create mild early-year consolidation. The company's unencumbered balance sheet and dependable recurring biopsy orders establish an elevated valuation floor against cyclical market pullbacks.
Q2 2031	66.52	+2.84%	+66.21%	Commercial contributions from expanded indication rollouts and international distribution partnerships supplement core domestic knee revenues. Strong return on invested capital and consistent cash conversion attract long-term value capital, supporting consistent quarter-over-quarter share appreciation.
Q3 2031	68.12	+2.41%	+70.21%	The five-year forecast culminates with the enterprise operating as a mature, self-funding regenerative medicine platform. Multiple compression toward realistic peer levels completes, leaving total equity returns driven by durable per-share operational earnings compounding.

Vericel is executing a fundamental operational transition from capital-intensive cleanroom construction to high-margin cash harvesting. The completion and regulatory approval of the Burlington manufacturing facility terminates peak capital expenditure, permitting gross margins to structurally hold above 74% as autologous batch throughput accelerates. Minimally invasive arthroscopic delivery expands the addressable orthopedic surgeon base into high-throughput outpatient centers, while federal burn procurement stabilizes non-dilutive baseline revenues. However, trading at an elevated trailing multiple in a restrictive interest-rate regime leaves the equity highly vulnerable to duration discount compression, requiring sustained operating margin expansion to offset systemic multiple derating.

Key insights

Fixed overhead absorption at Burlington converts incremental biological revenue into expanding operating cash flow, but high equity compensation dilutes headline cash conversion.
Arthroscopic delivery accelerates surgeon conversion velocity, yet stringent commercial payer prior authorizations and mandatory step therapies continually extend biopsy-to-implantation cash cycles.
A debt-free balance sheet and authorized share repurchases provide immediate downside support, but long-term terminal value remains exposed to competing allogeneic cartilage platforms.

Deep Dive

Market consensus views the company as an expensive specialty biopharma asset trading near eighty-four times trailing earnings in a restrictive monetary environment. Prevailing commentary anchors on post-expansion facility depreciation, quarterly surgical seasonality, and insurer prior-authorization friction. Investors largely assume that elevated interest rates will mechanically cap valuation multiples, treating autologous cell therapy as an artisanal, niche procedure nearing domestic market saturation.

Paywalled preview begins: Deep Dive

From this section to the end-of-preview notice below, research is provided as simplified HTML text and tables. Full access provides the complete interactive interface, charts and additional datasets.

Alpha Gap & Repricing Catalysts

Where the published AI consensus diverged from the market narrative

Market narrative

Alpha gap

The crowd underestimates underlying cash generation, creating mild underpricing on a cash-flow basis despite optical multiple stretch. The market fixates on trailing GAAP earnings depressed by facility buildout costs, missing that capital expenditures collapsed from 27% of revenue to single digits. This capex cliff unleashed forty-nine million dollars in trailing free cash flow. While arthroscopic delivery and fixed-cost absorption expand normalized owner earnings, the analytical challenge remains that elevated risk-free yields will compress terminal multiples, dampening equity gains relative to cash flow.

Repricing catalyst

The decisive catalyst cluster centers on consecutive quarterly earnings releases throughout 2027 confirming gross margins holding above 75% alongside annual free cash flow exceeding sixty million dollars. Accelerating biopsy conversion from MACI Arthro adoption and steady federal NexoBrid deliveries will demonstrate unmistakable operating leverage. This cash inflection will force institutional screening models to look past headline trailing multiples, prompting an upward valuation repricing as share buybacks reduce share float.

Published consensus context

Macro regime alignment

The macroeconomic backdrop represents a mixed setup. A hawkish monetary regime and elevated Treasury yields impose direct valuation compression on long-duration equities. However, zero debt, over two hundred million dollars in liquidity, and biologically non-discretionary joint preservation demand completely insulate core operations and cash generation from credit tightening and broader economic volatility.

Published consensus context

Advisor disagreement

The core debate centers on whether surging operational cash flows can overpower macro valuation headwinds. Bullish views argue that the post-Burlington capital expenditure collapse and arthroscopic surgeon expansion will unlock operating margins above 20% and fuel substantial buybacks, driving aggressive equity rerating. Conversely, skeptical views contend that paying eighty-four times trailing earnings in a 5% interest rate environment guarantees severe multiple compression, as bespoke autologous manufacturing faces structural margin ceilings and terminal allogeneic competition. Resolving this tension requires tracking whether quarterly GAAP operating margins sustainably exceed 12% through 2027.

Published scenario analysis

Base-case forces, risks, and opportunities

Top drivers and tailwinds

Burlington facility manufacturing scale unlock: FDA approval and commercial ramp of the Burlington production center eliminate historical cell-culture bottlenecks, tripling batch capacity. Concentrating manufacturing under automated cleanrooms spreads fixed labor and facility overhead across escalating volumes, expanding gross margins toward 76%. This structural leverage converts incremental cartilage repair revenue directly into substantial operating profit and unencumbered free cash flow. Expected impact: +32%.
MACI Arthro arthroscopic surgeon expansion: Commercial rollout of MACI Arthro instrumentation eliminates invasive open arthrotomy, expanding the addressable sports medicine orthopedic surgeon base from five thousand to over seven thousand clinicians. Arthroscopic delivery lowers patient recovery friction and accelerates biopsy-to-implant conversions, driving durable 20% annual cartilage repair volume growth and compounding high-margin biologic revenue over the five-year forecast horizon. Expected impact: +28%.
Autologous biologic monopoly and pricing power: Holding the sole FDA-approved autologous cellularized scaffold for knee cartilage repair creates an impenetrable regulatory and clinical barrier. Replicating proprietary patient-specific culturing protocols requires years of clinical trials and substantial capital investment, completely excluding generic competition. This monopolistic positioning secures premium pricing above $60,000 per implant, insulating gross margins and cash generation from inflationary shocks. Expected impact: +22%.
Post-capex cash allocation and repurchases: With major Burlington construction concluded, capital expenditure intensity collapsed from 27% of revenue to maintenance levels below 8%. Generating nearly $50 million in trailing free cash flow allows management to deploy its $200 million share repurchase program. Funded entirely by operating liquidity with zero debt, systematic share retirements neutralize compensation dilution and accretively compound earnings per share. Expected impact: +18%.

Top frictions and headwinds

Elevated interest rate valuation multiple compression: Trading at an elevated trailing earnings multiple near 84x and 52x EV/EBITDA leaves the stock acutely vulnerable to higher-for-longer discount rates. Benchmark 10-year Treasury yields hovering near 5% systematically compress long-duration equity multiples. Even robust operational earnings execution will see headline stock price appreciation heavily dampened as institutional valuation models derate specialty biopharma multiples toward historical norms. Expected impact: -24%.
Commercial insurer prior authorization friction: Commercial health insurers and Medicare Advantage plans continue enforcing aggressive utilization management, mandating step therapies and extensive conservative treatment documentation before approving costly cell implants. This administrative gatekeeping elongates the sales cycle from biopsy harvest to surgical implantation, increasing cancellation rates and requiring elevated corporate expenditures on reimbursement support personnel to defend procedural conversions. Expected impact: -14%.
Autologous cellular logistics margin ceiling: Personalized autologous therapy requires harvesting living human tissue, specialized cryogenic transport, individual batch culturing, and re-implantation. These bespoke operational logistics impose an irreducible cost floor that automation cannot fully eliminate. Cleanroom labor wage inflation and single-facility processing concentration permanently cap operating margins around 20%, preventing the company from achieving software-like biopharma profit conversion. Expected impact: -12%.
Burlington facility depreciation accounting drag: Capitalizing the state-of-the-art Burlington manufacturing complex more than doubled annual depreciation and amortization charges above $13 million. Maintaining dual facility operations during ongoing validation while cleanroom throughput scales introduces significant fixed overhead. This ongoing non-cash accounting drag compresses reported GAAP operating margins to single digits, discouraging conservative value investors who screen strictly on optical net income. Expected impact: -10%.

Tail risks

Disruptive off-the-shelf allogeneic cartilage emergence: A competing biotechnology developer could publish breakthrough Phase 3 clinical efficacy for an off-the-shelf allogeneic or synthetic chondral scaffold by 2029. Eliminating the invasive primary biopsy surgery and weeks of individualized cleanroom culturing would induce rapid surgeon substitution toward single-stage repairs. This technological disruption would rapidly dismantle the company's autologous moat, forcing steep price concessions and triggering terminal multiple collapse. Probability: +22%. Expected impact: -38%.
Burlington manufacturing cleanroom contamination shutdown: A severe microbial contamination event or adverse FDA cGMP inspection at the centralized Burlington cell-processing facility could force an immediate commercial suspension. Because autologous cell therapy involves perishable, patient-specific living tissues that cannot be inventoried or rapidly outsourced, an operational shutdown would instantly vaporize quarterly revenues, incur substantial remediation costs, and inflict lasting reputational damage among prescribing orthopedic surgeons. Probability: +16%. Expected impact: -40%.

Tail opportunities

MACI ankle talar indication label clearance: Successful pivotal readout from the Phase 3 MASCOT clinical study could trigger supplemental FDA approval for talar cartilage defects of the ankle by 2028. Ankle cartilage repair represents an underserved domestic market of over twenty thousand annual procedures with zero approved cellular competitors. Leveraging established sports medicine sales rails would unlock over $1 billion in incremental market opportunity, expanding earnings power by 30%. Probability: +36%. Expected impact: +32%.
International regulatory authorization and European commercialization: Securing marketing authorization from the UK MHRA followed by European distribution partnerships would establish the company's first commercial presence outside the United States. Utilizing Burlington's export-qualified capacity to serve European sports medicine demand would generate high-margin royalty and transfer revenues without heavy overseas commercial infrastructure outlays. This catalyst remains under 50% probability due to rigorous single-payer cost-effectiveness assessments across European health systems. Probability: +30%. Expected impact: +28%.

What to monitor

Thesis watchpoints

-- MACI quarterly revenue growth sustaining above 20% year-over-year alongside gross margins exceeding 75% through 2027 confirms surgical arthroscopy adoption momentum.

Key insights

Biopsy-to-implant conversion rates falling below 65% across two consecutive quarters signals mounting payer prior-authorization resistance or surgeon abandonment.
A material manufacturing suspension at Burlington or Phase 3 success of a competing off-the-shelf allogeneic therapy requires immediate thesis reassessment.

Company Financial Analysis

Vericel Earnings and Financials Analysis by AI

Financial figures available as of Sep 20, 2026. Only filings and source records available by this analysis date are included.

Earnings and financials

AI Review

Vericel has successfully transitioned from an unprofitable clinical-stage development firm into a commercial business generating positive operating income. For the trailing twelve months ended June 2026, revenue expanded to $306 million while net income reached $24.2 million, driven by strong 23% growth in MACI knee implants and growing burn treatment sales. This performance confirms that customer demand is expanding steadily. However, reported accounting profits experience sharp seasonal fluctuations. First quarters frequently show net losses due to annual insurance deductible resets, while fourth quarters deliver outsized profits as patients complete year-end procedures. The fundamental financial trajectory remains positive as rising case volumes absorb fixed corporate overhead.

Revenue, earnings, and cash flow

The table compares up to five fiscal years of revenue, net income, and free cash flow available to this analysis.

Revenue, net income, and free cash flow history
Fiscal year	Revenue	Net income	Free cash flow
2025	USD 276.3M	USD 16.5M	USD 24.7M
2024	USD 237.2M	USD 10.4M	USD -5.8M
2023	USD 197.5M	USD -3.2M	USD 7.8M
2022	USD 164.4M	USD -16.7M	USD 10.1M
2021	USD 156.2M	USD -7.5M	USD 21.1M

Valuation context: historical P/E

The table compares up to five fiscal years of point-in-time valuation evidence available to this analysis.

Historical price-to-earnings ratios
Fiscal year	P/E	Earnings basis	Currency basis	Ticker / reporting
2025	>100x	TTM	Native	USD / USD
2024	>100x	TTM	Native	USD / USD
2023	--	TTM	Loss-making	USD / USD
2022	--	Annual	Loss-making	USD / USD
2021	--	Annual	Loss-making	USD / USD

P/E uses historical market capitalization and earnings known at each period. Cross-currency observations are normalized to USD using point-in-time FX rates.

Profitability and margins

AI Review

Gross profit margins have expanded structurally from under 69% in 2023 to over 74% in 2025, driven by premium product pricing and improved cell-culturing efficiency. Because autologous cell therapy manufacturing costs are largely fixed, processing higher patient volumes through automated Burlington bioreactors allows gross margins to hold near 75%. Below gross profit, GAAP operating margins sit near 6% due to high facility depreciation, commercial sales force investments, and stock-based employee compensation. As specialized sales territories mature and batch throughput expands across the forecast horizon, operating leverage should gradually expand operating profitability toward mid-teens.

The table compares up to five fiscal years of operating income and reported profitability margins.

Operating income and margin history
Fiscal year	Operating income	Operating margin	Net margin
2025	USD 11M	4.0%	6.0%
2024	USD 4.5M	1.9%	4.4%
2023	USD -6.5M	-3.3%	-1.6%
2022	USD -17.1M	-10.4%	-10.2%
2021	USD -7.9M	-5.0%	-4.8%

Balance sheet and leverage

AI Review

Vericel commands a fortress balance sheet characterized by zero funded bank debt and approximately $227 million in cash and short-term investments as of mid-2026. A current ratio above 5.0 and an undrawn $150 million credit line demonstrate excellent liquidity, completely protecting business operations from high interest rates and credit market volatility. While reported financial liabilities include roughly $93 million in long-term building lease obligations for manufacturing cleanrooms, these represent ongoing operational facilities rather than refinancing debt. Management possesses total balance-sheet freedom to self-fund clinical trials and repurchase shares without depending on external capital.

The table compares up to five fiscal years of debt, liquidity, net cash or debt, and current-ratio evidence.

Balance sheet leverage and liquidity history
Fiscal year	Total debt	Cash + short-term investments	Net cash / (debt)	Current ratio
2025	USD 98.3M	USD 137.5M	USD 1.8M net cash	5.03x
2024	USD 98.9M	USD 116.2M	USD 24.3M net debt	4.23x
2023	USD 88M	USD 109.6M	USD 19M net debt	4.49x
2022	USD 47.6M	USD 119.5M	USD 3.5M net cash	4.99x
2021	USD 50.2M	USD 103.4M	USD 18.1M net cash	6.08x

Net debt below zero is displayed as net cash. Current ratio is current assets divided by current liabilities.

Capex and investment intensity

AI Review

Management has completed a major multi-year spending cycle after constructing and commissioning its advanced manufacturing plant in Burlington, Massachusetts. Capital spending peaked in 2024 at 27% of revenue during cleanroom construction before falling sharply to under 10% in 2025 and lower in 2026. This deliberate reduction in construction spending has liberated substantial operational liquidity. Because foundational manufacturing capacity is now installed for the next decade, ongoing maintenance investment requires less than 5% of revenue. This shift allowed trailing free cash flow to surge to nearly $50 million, enabling management to direct surplus capital toward an authorized $200 million share repurchase program.

The table compares up to five fiscal years of capital expenditure and research-and-development investment.

Capital expenditure and research and development history
Fiscal year	Capital expenditure	R&D spend
2025	USD 27.2M	USD 27.6M
2024	USD 64M	USD 24.8M
2023	USD 27.5M	USD 21M
2022	USD 7.6M	USD 19.9M
2021	USD 7.9M	USD 16.3M

Immutable published data

Averaged consensus horizons

The table preserves this publication's original rating, return, and advisor-agreement measurements by forecast horizon.

Horizon	Rating	Score incl. dividends	Compounded return incl. dividends	Direction agreement	Snapshot
1Y	NEUTRAL	91	+12.2%	Not available	ORIGINAL
5Y	NEUTRAL	113	+84%	Not available	ORIGINAL

Averaged consensus scenarios

The table outlines the frozen bear, consensus, and bull price scenarios for each published forecast period.

Period	Date	Bear case	Consensus	Bull case	AI Advisors
+3M	December 18, 2026	38.02	42.05	44.02	14
+6M	March 18, 2027	38.75	41.76	44.52	14
+9M	June 18, 2027	37.97	43.24	47.63	14
+1Y	September 18, 2027	39.49	44.9	50.49	14
+15M	December 18, 2027	41.47	47.72	54.53	14
+18M	March 18, 2028	39.81	47.45	56.71	14
+21M	June 18, 2028	41	49.87	60.68	14
+2Y	September 18, 2028	40.18	51.17	63.72	14
+27M	December 18, 2028	42.59	53.96	68.18	14
+30M	March 18, 2029	40.46	54.16	70.22	14
+33M	June 18, 2029	42.08	56.74	74.44	14
+3Y	September 18, 2029	40.82	58.59	78.16	14
+39M	December 18, 2029	42.86	61.73	82.85	14
+42M	March 18, 2030	41.57	62.15	85.33	14
+45M	June 18, 2030	43.24	64.97	90.31	14
+4Y	September 18, 2030	42.37	66.42	94.82	14
+51M	December 18, 2030	44.49	69.51	101.46	14
+54M	March 18, 2031	42.71	69.46	103.49	14
+57M	June 18, 2031	43.99	71.71	108.66	14
+5Y	September 18, 2031	44.07	73.64	113.01	14

Frozen comparison context

SPDR S&P 500 ETF Trust forecast context

The benchmark definition and forecast path are frozen with this publication so future benchmark changes do not rewrite the historical comparison.

Benchmark snapshot: 761.69 on September 18, 2026

Period	Date	Bear case	Consensus	Bull case
+3M	December 18, 2026	723.6055	750.2647	769.3069
+6M	March 18, 2027	701.8973	736.44	784.693
+9M	June 18, 2027	695.1	743.3975	808.2338
+1Y	September 18, 2027	681.198	755.1476	816.3162
+15M	December 18, 2027	688.01	776.2182	840.8057
+18M	March 18, 2028	701.7702	787.1259	857.6218
+21M	June 18, 2028	722.8233	802.8344	883.3504
+2Y	September 18, 2028	730.0515	812.0465	892.1839
+27M	December 18, 2028	751.9531	839.1839	927.8713
+30M	March 18, 2029	766.9921	850.5008	946.4287
+33M	June 18, 2029	782.332	872.3935	965.3573
+3Y	September 18, 2029	790.1553	885.5111	975.0109
+39M	December 18, 2029	805.9584	909.5618	1,004.2612
+42M	March 18, 2030	822.0776	916.132	1,024.3464
+45M	June 18, 2030	830.2984	936.5109	1,055.0768
+4Y	September 18, 2030	830.2984	947.3438	1,065.6276
+51M	December 18, 2030	855.2073	969.5876	1,097.5964
+54M	March 18, 2031	872.3114	979.9863	1,119.5483
+57M	June 18, 2031	889.7577	999.6043	1,141.9393
+5Y	September 18, 2031	898.6553	1,011.7644	1,153.3587

Behind the synthesis

How each opinion shapes the consensus

14 opinions · 100% allocated

The reports exhibit strong independent consensus regarding operational fundamentals: the Burlington facility completion eliminates capital expenditure drag, releasing approximately $50 million in trailing free cash flow, while MACI Arthro expands surgeon adoption. However, reports sharing optimistic assumptions often extrapolate unadjusted EBITDA without adequately deducting stock compensation, facility depreciation, and payer friction. Conversely, the strongest credible contrarian perspective rightly emphasizes that paying 84x trailing earnings in a 5% interest-rate regime creates severe multiple compression risk, even if revenue compounds above 15%. Extreme outlier projections—such as frictionless multiple expansion to $140 or rapid catastrophic obsolescence below $22—lack near-term empirical backing. Weighting therefore favors reports that balance proven cash-flow inflection against rigorous discount-rate discipline, rewarding frameworks that reconcile operating leverage with structural multiple contraction while downweighting unhedged momentum narratives.

AI RESEARCHER

Universal Investor AI

The Polymath

GPT-6 Astra

Weight12.0/100

Demonstrating superior analytical rigor, this report reconciles primary SEC filings, verifies lease liabilities versus funded debt, and accounts for equity compensation drag. Its sober 9% annual return expectation properly discounts platform hype, warranting the highest weight.

AI RESEARCHER

Universal Investor AI

The Polymath

Opus 5

Weight11.0/100

Backed by primary earnings transcript verification, this analysis sharply identifies the duration tax on high multiples and highlights the stock compensation gap in adjusted EBITDA. Its grounded, cash-focused trajectory provides exceptional decision utility.

AI RESEARCHER

Sherlock Holmes AI

The Whistleblower

Gemini 3.8 Flash

Weight8.0/100

Grounding its thesis in forensic verification of post-capex cash generation, this report presents a balanced view of operating leverage versus terminal multiple contraction. Its reasonable 26x forward multiple and focus on conversion watchpoints justify an above-average weight.

AI RESEARCHER

Warren Buffett AI

The Value Seeker

Gemini 3.8 Flash

Weight8.0/100

This analysis excels by focusing on owner earnings, working capital stability, and fortress balance-sheet insulation. Its conservative terminal multiple of 22x and clear-eyed view of sunk Burlington capex provide sound economic reasoning that warrants strong weighting.

AI THINKER

Warren Buffett AI

The Value Seeker

Gemini 3.8 Flash

Weight8.0/100

This report correctly identifies that heavy non-cash facility depreciation obscures underlying owner cash flows. Its focus on autologous biologic moats and realistic 25x terminal owner-earnings multiples provides credible long-term perspective, supporting a solid weight.

AI RESEARCHER

Elon Musk AI

The Visionary

Gemini 3.8 Flash

Weight7.0/100

This report accurately identifies the thermodynamic bottlenecks of autologous manufacturing and the mathematical inevitability of multiple compression in a high-rate regime. However, it overstates near-term obsolescence from allogeneic competitors, warranting a moderate weight that values its disciplined valuation caution.

AI RESEARCHER

Michael Burry AI

The Vulture

Gemini 3.8 Flash

Weight7.0/100

Offering essential contrarian rigor, this report highlights the vulnerability of an 84x trailing multiple against 5% sovereign bond yields and notes insider selling. While somewhat overly punitive regarding top-line durability, its valuation discipline survives scrutiny.

AI THINKER

Universal Investor AI

The Polymath

Gemini 3.8 Flash

Weight7.0/100

This report thoroughly examines post-Burlington free cash flow mechanics and institutional NexoBrid integration. However, its baseline assumption of 23% operating margins somewhat downplays specialized biologic selling expenses, warranting a balanced intermediate weight.

AI THINKER

Superintelligence AI

The Anthropologist

Gemini 3.8 Flash

Weight7.0/100

Providing excellent analysis of deductible-driven seasonality and cleanroom thermodynamic constraints, this report realistically models earnings growth being partially consumed by multiple compression toward 28x. Its balanced causal framework justifies an above-average weight.

AI RESEARCHER

Niccolo Machiavelli AI

The Insider

Gemini 3.8 Flash

Weight6.0/100

The analysis effectively captures regulatory moats under FDA biologics oversight and sovereign backing via BARDA. However, it underestimates rate-driven multiple compression and models aggressive long-term price targets that rely on flawless execution across international markets.

AI RESEARCHER

Superintelligence AI

The Anthropologist

Gemini 3.8 Flash

Weight6.0/100

This perspective provides valuable insight into arthroscopic adoption mechanics and fixed-cost absorption. Nevertheless, its projection of Adjusted EBITDA margins reaching 37% minimizes ongoing cleanroom labor inflation and commercial salesforce overhead, requiring a measured weighting.

AI RESEARCHER

Ray Dalio AI

The Strategist

Gemini 3.8 Flash

Weight5.0/100

The framework effectively links economic machine cycle transitions to cash flow liberation and zero-debt balance sheet resilience. However, its compounded trajectory assumes sustained multiple expansion that conflicts with higher-for-longer cost-of-capital realities.

AI RESEARCHER

J.P. Morgan AI

The Titan

Gemini 3.8 Flash

Weight4.0/100

While thoroughly evaluating the Burlington manufacturing scale and commercial monopoly dynamics, this assessment models extreme multiple resilience and aggressive earnings targets. It severely downweights monetary tightening drag and payer step-therapy frictions, justifying a reduced relative allocation.

AI RESEARCHER

Universal Investor AI

The Polymath

Gemini 3.8 Flash

Weight4.0/100

While identifying commercial inflection drivers and buyback dynamics, this report relies on overly aggressive price trajectory checkpoints that outpace plausible multiple compression constraints. Its optimistic compounding path requires a discounted weighting.

Skip to references

Research Provenance

References & Context

This Vericel consensus analysis combines structured market evidence with independent AI-agent forecasts. External references below are limited to sources recorded by the researcher agents for this forecast batch.

Primary analysis inputs

iPulse AI Multi-Agent Forecasts — independent analyst personas, model outputs, and consensus synthesis.
iPulse AI Global Events Context — macroeconomic, geopolitical, regulatory, and industry-event context.
Structured market history — prices, distributions, volatility, identifiers, and listing metadata.
Company earnings and financial statements — revenue, profitability, balance-sheet, cash-flow, and investment trends.
Researcher web evidence — public sources consulted to challenge and contextualize the forecast thesis.

Independent AI Advisor panel

AI Advisors: 14
AI Researchers: 11
AI Thinkers: 3

Sources retained from AI Researcher searches

Asset-specific · Researcher web

Showing the top 15 of 61 deduplicated sources retained for this batch.

01Package Insert - MACIfda.gov
02Federal Reserve Board - Federal Reserve issues FOMC statementfederalreserve.gov
03https://www.sec.gov/Archives/edgar/data/887359/000162828026050815/ex991earningsreleaseq22026.htm?utm_source=openaisec.gov
04Press Release of Vericel Corporation ...sec.gov
05vcel-20251231sec.gov
06vcel-20260630sec.gov
07VERICEL CORPORATION - DEF 14Asec.gov
08Vericel Reports Second Quarter 2026 Financial Results, Raises Full-Year Financial Guidance and Announces Share Repurchase Program - BioSpacebiospace.com
09VCEL Stock Quote Price and Forecast | CNNcnn.com
10Vericel Corp (VCEL) Q2 2026 Earnings Call Transcript - Equiblesequibles.com
11Vericel Q2 Earnings Call Highlightsfinance.yahoo.com
12Vericel Q2 2026 slides: 22% revenue growth, first buyback By Investing.cominvesting.com
13Vericel Announces FDA Approval of New State-of-the-Art Advanced Therapy Manufacturing Facility | Vericel Corporationinvestors.vcel.com
14Vericel Reports First Quarter 2026 Financial Results and Raises Full-Year Financial Guidance | Vericel Corporationinvestors.vcel.com
15Vericel Reports Fourth Quarter and Full-Year 2025 Financial Results | Vericel Corporationinvestors.vcel.com

And 46 more sources were used and retained in the batch inventory.

Context retained with this Consensus

The same public-safe market, global-event, and fundamental context supplied to the AI Advisor panel.

Global context snapshot

2025 Full-Year Global Market and World-Events Context

Download Archived Snapshot

Coverage 2025-01-01 to 2025-12-31 · Knowledge cutoff 2025-12-31

This full-year context package covers the principal geopolitical, economic, monetary-policy, technology, trade, energy, and institutional developments that shaped global markets during 2025. It gives the forecasting model a chronological account of major world events together with their likely transmission into growth, inflation, interest rates, supply chains, commodities, currencies, public markets, and sector-level investment conditions.

The package also includes monthly and quarterly macroeconomic and cross-asset reference tables spanning US and international growth, central-bank policy, sovereign yields, major equity indices, foreign exchange, energy, industrial and precious metals, and digital assets. Quarterly and full-year high-impact summaries are integrated; monthly quantitative series remain working values pending final audit, and that qualification is part of the preserved context.

Top 3 market shifts from 2025 Full-Year Global Market and World-Events Context
Top 3 Market Shifts From File	Date	Status
DeepSeek shock and AI economics reset	2025-01-27	OPEN ENDED TREND
US tariff regime escalation and trade-system rupture	2025-02-01	ACTIVE POLICY REGIME
Federal Reserve easing cycle after a prolonged hold	2025-09-17	ACTIVE POLICY REGIME

Representative Sources of the Context File

Federal Reserve US Bureau of Labor Statistics US Bureau of Economic Analysis US Treasury US Energy Information Administration Reuters World Associated Press World News BBC World

And more sources from the retained context package.

2026 Year-to-Date Global Market and World-Events Context Through September 20

Download Archived Snapshot

Coverage 2026-01-01 to 2026-09-20 · Knowledge cutoff 2026-09-20

January 1-September 20, 2026: monetary tightening, energy security, trade restrictions, AI financing and divergent growth; five leading market themes.

Fed raised rates to 3.75%-4.00%; ECB hike is in force and BOJ increase starts September 24. Markets through September 18, bitcoin through September 19.

Top 3 market shifts from 2026 Year-to-Date Global Market and World-Events Context Through September 20
Top 3 Market Shifts From File	Date	Status
Renewed monetary tightening amid persistent inflation	2026-01-30	ACTIVE POLICY REGIME
Iran/Hormuz conflict and wider energy-security disruption	2026-02-28	ONGOING
Tariff legal reset and strategic supply restrictions	2026-02-20	ACTIVE POLICY REGIME

Representative Sources of the Context File

Federal Reserve US Bureau of Labor Statistics European Central Bank International Monetary Fund Reuters World Associated Press World News

And more sources from the retained context package.

Fundamental context

Income statement

9 fields

depreciationAndAmortization · ebit · ebitda · grossProfit · +5 more fields

Balance sheet

12 fields

cash · commonStockSharesOutstanding · longTermDebt · netDebt · +8 more fields

Cash flow

5 fields

capitalExpenditures · dividendsPaid · freeCashFlow · salePurchaseOfStock · +1 more field

annual: 2014-12-31–2025-12-31, 12 periods; quarterly: 2023-09-30–2026-06-30, 12 periods

Currencies cited: USD (quote USD; primary reporting USD; converted/valuation USD).

End of the paywalled preview

The excerpt from Deep Dive to this notice is the simplified paywalled content included on this page. A signed-in, verified account with the required subscription provides the full interactive interface and the additional research, datasets and tools listed below.

Those additional materials are not included in this preview and cannot be revealed by removing its visual restrictions.

Additional with full access

Individual AI Advisor reports
- Separate investment theses, scenarios, factors, risks and opportunities
- Quarterly forecast events and supporting citations
- Published advisor configuration snapshots
Interactive research tools
- Zoomable forecast and benchmark comparisons
- Currency and dividend assumptions
- Additional datasets and eligible historical research

Explore complete public research examples

These public assets show the complete AI Consensus research. Their findings concern those assets, not this report.